Pfizer – Approaches to Implement Bispecific Antibodies into Clinical Practice, Increase Awareness and Improve Delivery of Quality of Care for Patients with Multiple Myeloma – RFP

This RFP is being issued by both organizations. Myeloma Canada is the lead organization for review and evaluation of proposals. A review committee, led by Myeloma Canada, will make decisions on which proposals will receive funding.

For all independent quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program.

Geographic Scope: Canada

Clinical Area: Relapsed/Refractory Multiple Myeloma

Link to full RFP: Approaches to Implement Bispecific Antibodies into Clinical Practice, Increase Awareness and Improve Delivery of Quality of Care for Patients with Multiple Myeloma

Application Due Date: June 1, 2023

Specific Area of Interest: The intent of this RFP is to support QI initiatives that will increase equitable access to and delivery of quality care for patients with multiple myeloma with the goal of optimizing the care and outcomes of patients.

Proposals in the following topic areas are strongly encouraged:

• Support for clinicians on topics such as treatment selection, emerging novel mechanism of action (MOA) of BsAbs, and therapy and patient management
• Strategies for coordinating BsAb therapy management between oncologists and the multidisciplinary and multispecialty care team
• Transition of care from in-patient to out-patient setting and therapy scheduling, dosing, and management of side effects
• Adverse event (AE) management-training and processes for how to anticipate, mitigate and manage adverse events associated with BCMA-directed antibodies in RRMM
• Multi-disciplinary care models (e.g., nurse navigator, oncology nurse)
• Methods for addressing disparities (geographic, racial, financial) and access to care
• Integration of strategies to improve health literacy for the patient throughout their cancer journey
• HCP Education addressing BsAb therapy management, with focus on AEs of special interest such as CRS, immune effector cell-associated neurotoxicity syndrome (ICANS), infections